Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer

Journal of Urology

Volumn 155, Issue 3, 1996, Pages 858-862

  Hofmann, Rainer ^a   Lehmer, Antonie ^a   Hartung, Rudolf ^a   Robrecht, Cordula ^a   Buresch, Markus ^a   Grothe, Franziska ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

kidney neoplasms; plasminogen inactivators; prognosis; urokinase

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; PLOIDY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030061899     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66328-6     Document Type: Article

References (20)

1. Selli, C., Hinshaw, W. M., Woodard, B. H. and Paulson, D. F.: Stratification of risk factors in renal cell carcinoma. Cancer, 52: 899, 1983.
2. Lieber, M. M., Tomera, F. M., Taylor, W. F. and Farrow, G. M.: Renal adenocarcinoma in young adults: survival and variables affecting prognosis. J. Urol., 125: 164, 1981.
3. Hollas, W., Hoosein, N., Chung, L. W., Mazar, A., Henkin, J., Kariko, K., Barnathan, E. S. and Boyd, D.: Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thromb. Haemostasis, 68: 662, 1992.
4. Danø, K., Andreasen, P. A., Grøndahl-Hansen, J., Kristensen, P., Nielsen, L. S. and Skriver, L.: Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res., 44: 139, 1985.
5. Schmitt, M., Jänicke, F. and Graeff, H.: Tumor-associated proteases. Fibrinolysis, suppl., 4: 3, 1992.
6. Hollas, W., Blasi, F. and Boyd, D.: Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res., 51: 3690, 1991.
7. Vindeløv, L. L., Christensen, I. J. and Nissen, N. I.: A detergent-trypsin method for the prepartation of nuclei for flow cytometric DNA analysis. Cytometry, 3: 323, 1983.
8. Hawkins, D. M.: Testing the sequence of observations for a shift in location. J.A.S.A., 72: 180, 1977.
9. Kirchheimer, J. C., Pflüger, H., Ritschl, P., Hienert, G. and Binder, B. R.: Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors. Invasion Metastasis, 5: 344, 1985.
10. Gorelik, U., Lindner, A. and Mayer, M.: Protease and plasminogen activator activity in human bladder carcinoma. Brit. J. Urol., 66: 170, 1990.
11. Hasui, Y., Suzumiya, J., Marutsuka, K., Sumiyoshi, A., Hashida, S. and Ishikawa, E.: Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder. Cancer Res., 49: 1067, 1989.
12. Cubellis, M. V., Andreasen, P., Ragno, P., Mayer, M., Danø, K. and Blasi, F.: Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc. Natl. Acad. Sci., 86: 4828, 1989.
13. Cubellis, M. V., Wun, T. C. and Blasi, F.: Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J., 9: 1079, 1990.
14. Schmitt, M., Jänicke, F. and Graeff, H.: Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagulation Fibrinolysis, 1: 695, 1990.
15. Jänicke, F., Schmitt, M. and Graeff, H.: Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Sem. Thromb. Hemostasis, 17: 303, 1991.
16. Duffy, J. M., Reilly, D., Nolan, N., O'Higgins, N., Fennelly, J. J. and Andreasen, P.: Urokinase plasminogen activator, a strong and independent prognostic marker in breast cancer. Fibrinolysis, suppl., 4: 55, 1992.
17. Lehmann, K., Plas, E., Gautschi, K. and Hauri, D.: Prognostic value of urokinase plasminogen activator for prostatic carcinoma. Urol. Int., 52: 159, 1994.
18. Störkel, S., Thoenes, W., Jacobi, G. H. and Lippold, R.: Prognostic parameters of renal cell carcinoma - a new approach. Eur. Urol., 16: 416, 1989.
19. Frixen, U. H., Behrens, J., Sachs, M., Eberle, G., Voss, B., Warda, A., Löchner, D. and Birchmeier, W.: E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J. Cell. Biol., 113: 173, 1991.
20. Wilhelm, O., Weidle, U., Höhl, S., Rettenberger, P., Schmitt, M. and Graeff, H.: Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Letters, 337: 131, 1994.